KRAS and neoplasm: ABab-I mice mount robust CD8+ T cell responses in vivo against viral (Cytomegalovirus (CMV), Human Papillomavirus (HPV)), tumor-associated antigens (MAGE-A12), and tumor-specific neoantigens (mutant KRAS and CALR).